Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals: 2 sponsored US clinical trials, 2 recruiting.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, with 1 trials.
Mid-pack sponsor footprint
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
What is open in the Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals pipeline
2 recruiting of 2 indexed (100% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals page
2 registered trials is a research-attention snapshot, not an endorsement of Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals or any single study.
- 2 of Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma is the condition Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals pipeline card: 2 registered trials from official public datasets.Report a data error.